Monday, January 28, 2013

Today's Datapoint

22% … was the increase in spending in 2012 on oral oncology drugs, according to Peter Wickersham, senior vice president, cost of care for Prime Therapeutics.
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)